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1. Introduction 
The mechanism of disease in venous thromboembolsm (VTE) is mentioned, with emphasis 
on the rarer types of the disease. Next the conditions for approval of claims under the 
Danish Patient Insurance law are drawn up, and the typical situations for approval of VTE 
are listed. In the database of the DPIA we found 688 claims with this disease, and of these 
421 were approved. The different types of VTE are examined, and the possibilities for 
prevention are discussed.  
2. Of venous thromboembolism 
Venous trombosis is usually located in the veins of the lower extremity. The thrombosis 
probably has its origin in the valve pockets of the veins of the lower leg. There are several  
pathogenetic factors, but a common denominator is reduction of flow velocity in the veins. 
This may occur in a varity of situations, e.g.: 
1. During aneasthesia it has been shown that the diameter of the veins increase, and thus 
the velocity of the flow decreases. At the same time the operative trauma increases the 
readyness of the thrombotic system.   
2. In a number of different trauma situations to the leg, where immobilisation in casts or 
splints is used, rendering the venous muscle pump dysfunctionate, 
3. In acute stroke, the afflicted leg is left without its normal venous muscle pump  
These are classic examples of patients that may suffer a deep venous trombosis (DVT) or 
more severely a pumonary embolism (PE). 
There are many clinical examples of variatons on the theme. 
The thrombosis may begin in the popliteal or femoral vein progressing centrally until it 
breaks off and sends its potentially fatal embolism to the lungs. It may also have its origin in 
the iliac veins, in which case the diameter of the ensuing embolism is sufficient large to close 
off the entire pulmonary artery, causing immediate death.  
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A special variety of the disease exists, where an obstruction is present at the iliac venous 
junction. This is called the left iliac vein syndrome, and it is normally not associated with 
pulmonary embolism, as the lumen of the left common vena iliaca is partially obstructed by 
a fine net of the endothelium at the junction. The compression from the crossing of the right 
common iliac artery adds to the obstruction. 
In some cases the source of embolism is located in a venous malformation, and the 
thrombi to the lungs may be small and not easily clinically detectable. The pressure in the 
pulmonary artery increases slowly over months with the continuing pulmonal 
embolization causing cronical cor pulmonale. The foramen ovale may open under the 
increased pressure in the right side of the heart, releasing minor emboli to the arterial 
circulation. The end result is usually cardiac arrest due to the increased pressure with 
dilation of the right ventricle. 
In rare cases the thrombosis occurs in the veins of the upper extremity. The size of emboli 
from the arms is not sufficient to give any serious problem from the lungs, but it is 
important to know that this possibility exists.  
Thombosis in the mesenteric veins is a very rare, but potentially deadly disease. The onset of 
symptoms is much slower than that of arterial vascular iscaemia, where as a rule you have 
only 6 hours from the embolization to completion of thrombectomy, if gangrene and 
resection should be prevented. In venous ishaemia there are often days or weeks of 
symptoms before the onset of gangrene, and if the ischaemia has progressed to gangrene, a 
simple resection will often be sufficient. Venous intestinal ischaemia is usually not 
recognized until laparotomy, and it may be very difficult to make the diagnosis by 
laparoscopy alone. 
Thrombosis in the venous sinuses of the brain is an important side effect to birth control 
drugs, and must always be considered as a differential diagnosis when a patient on the pill 
develops symptoms from the brain. 
Finally, another inborn vascular anomaly has bearing on the embolisation from the veins of 
the lower limbs: The foramen ovale, which normally closes at the time of birth, will sometimes 
remain open and allow emboli from the right side to cross over to the left side and continue 
in the arterial system. This is known as “paradox” embolisation, and is important to 
consider, when a patient at risk for venous thrombosis suffers an arterial embolus. The 
frequency of patent foramen ovale in autopsy studies is about 20 %, so this a significant risk, 
as the frequency of deep venous thrombosis is equally high (1). 
The disease known as thrombophlebitis, where a subcutaneous vein is inflamed and 
thrombosed, has nothing in common with DVT. In the major part of the 20th century it was 
thought that thrombosis might spread from the superficial veins to the femoral venous 
system through the sapheno-femoral junction, wherefore acute ligature of the junction was 
advised. This indication for the sapheno-femoral ligature has since been abandoned. Also, 
the practice of anticoagulation with thrombophlebitis is no longer advised.  
3. The Danish patient insurance law 
In Denmark, patients or relatives may file a claim if their medical treatment results in an 
injury or an unexpected side effect. The independent Danish Patient Insurance 
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Association (DPIA) will consider these claims. The DPIA operates on a no-blame, no-fault 
basis and does not take any legal action beyond assessing damages. As a result, patients 
may file a claim with the DPIA free of charge with the sole purpose of seeking financial 
compensation. Thus, the injured patient is spared the expense of legal fees and the trouble 
of going to court (2). 
In general, financial compensation may be granted under any one of the following 
conditions:  
1. an experienced specialist would have acted differently, whereby the injury would have 
been avoided,  
2. defects in or failure of the technical equipment were of major concern with respect to 
the incident,  
3. the injury could have been avoided by using alternative treatments, techniques or 
methods if these were considered to be equally safe and potentially offer the same 
benefits, and finally, 
4. the injury is rare, serious, and more extensive than the patient should be expected to 
endure. 
Compensation is calculated based on the extent of pain and suffering, reduced income, 
reduced ability to work, and medical expenses as well as whether the injury could be 
expected to be permanent. Compensation is rendered if the calculated amount exceeds 
1,500 €. The government pays the compensations. After the decision has been made, the 
patient may file an appeal to the Patient Damage Appeal Board and further through the 
courts of law. From 1996 to 2010, the DPIA received 64.400 claims; 34.9 % of these were 
approved. 
4. Venous tromboembolism and patient injury 
VTE may be judged to be a patient injury in the following situations: 
- when an injury was sustained, because the diagnosis of VTE was not made in a 
situation, where an experienced specialist would have done so, 
- when VTE has been caused by giving a treament wthout the  proper prophylaxis,  
- when a drug was prescribed that caused VTE, 
- when the treatment of VTE was not up to the standard of the experienced specialist 
- when the patient suffered more than he should be expected to bear considering his 
basic disease, the risk of treatment and whether the complication was rare and 
serious. 
In such cases the DPIA may consider to give compensation if the other conditions of the law 
are met. 
5. VTE and the database of the DPIA 
Since 1996 we have maintained a database of all claims. Until the end of 2010, there were 
688 claims, where the complication was VTE. In table 1 is shown the number of patients 
with DVT alone, the patients who also had PE, and the patients with rare thombosis. The 
rates of approval of the claims are around 60 % compared to the average rate of 35 % of 
the DPIA. 
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Complication N N approved Rate of approval 
Deep venous thrombosis in the legs alone 390 226 58 % 
Pulmonary embolism 266 176 66 % 
Rare venous thrombosis 32 19 59 % 
Total 688 421 61 % 
Table 1. DVT and PE in the material. 
There were 42 patients who died because of the patient injury (6.1 %). 
The patients could be divided in 5 sub-categories after the nature of their disease and 
circumstances surrounding the injury (Table 2). 
 
Invasive procedures 391 
Birth control drugs 193 
Other drugs 13 
Non-operative fracture treatment 30 
Missed diagnosis 15 
Rare and miscellaneus 46 
Total 688 
Table 2. Categories of patients. 
VTE after an open intervention was the largest group with 391 patients. The cause of injury 
was usually failing to give the correct prophylaxis, or omitting to give any prophylaxis at 
all. The specialities involved are seen in table 3. 
 
Speciality N invasive procedures N approved 
Orthopedic surgery 226 128 
Surgery 94 52 
Internal medicine 23 10 
Gynaecology & Obstetrics 18 11 
Neurosurgery 13 9 
General practice 2 2 
OtoRhinoLaryngology 5 5 
Anaestesia 3 2 
Radiology 4 3 
Neurology 1 1 
Onchology 1 0 
Dental surgery 1 1 
Total 391 224 
Table 3. The number of patients with VTE treated in the different specialities. 
Of these, 27 patients died as result of the injury. There were 224 patients, who had their 
claims approved by the DPIA. Compensation was paid to 218 patients to the total amount of 
€ 6.127.365.  
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6. VTE and treatment with female hormones 
The other large group was 193 patients with DVT or PE, who had birth control medication 
(173 patients) or treatment of menopausal conditions (20 patients) prescribed by their 
physician, and suffered VTE as a result. Their claims were approved in 138 cases, and € 
2.956.248 was paid to 134 patients. Only 5 women died, but it must be borne in mind that 
these were completely healthy women. In 17 cases it was later established that the patient 
had a coagulation defect, usually the Leiden factor-5 mutation. 
There were at times several factors that contributed to the onset of thrombosis in these 
patients.  Thus it was discussed which factor was the crucial one, when e.g. a young woman 
who was on birth control pills and had a body mass index of 34, undertook a long air travel 
and suffered VTE? The coagulation experts that we have consulted thought that the VTE 
would not have happened without the birth control medication, and that the contribution of 
the other factors was minor in comparison. 
7. Treatment with other drugs 
In 12 cases the VTE was thought to be caused by other drugs (Table 4). It was mainly claims 
with faulty use of anticoagulants that were approved. One patient died. 
Other drugs N N approved 
Vitamin K antagonist 5 3 
Angiotensin converting enzyme 1 1 
Immuneglobuline 2 1 
Docetaxel 3 0 
Cox-2 inhibitor 1 0 
Prednisolone 1 0 
 13 5 
Table 4. The other drugs involved in VTE claims. 
Non-operative treatment of fractures and joint injuries was the cause of 30 claims, shown in 
table 5. 
Non-operative treatment of fractures and joint injuries N N approved 
Spine 3 1 
Lower extremity 27 13 
 30 14 
Table 5. VTE after non-operative treatment. 
It was of course mainly fractures in the lower extremity that were afflicted because of the 
need for immobilization. Usually in the DPIA, VTE is thought to be a side effect of the 
fracture itself, and it is therefore not eligible for compensation. In 4 cases however, the 
diagnosis was missed, and in one further case the appeal board decided that the diagnosis 
should have been made at the time, when the cast was cut open because of swelling. In the 
last 9 approved cases there were individual indications for giving anticoagulants that were 
not recognized at the time of fracture. Four patients died as a result of the patient injury. In 
many of the non-approved cases, the question was whether the experienced specialist 
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would have used prophylaxis? For example, the recommended program for a non-displaced 
fracture of the tibia states that prophylaxis against VTE is not necessary; yet the frequency of 
DVT in these patients is 15 %. If we were to extend the program of prophylaxis to 
encompass ambulatory patients with a walking cast, these patients would only rarely suffer 
DVT, and some lives would be spared.  
8. Missed diagnosis 
In 15 cases without fractures or operation, the diagnosis of VTE was missed. The claim was 
approved in 12 cases (Table 6). These cases were evenly distributed among primary and 
secondary practice. Three patients died as result of the injury 
 
 N Approved 
Hospitals 7 6 
Primary sector 8 6 
 15 12 
Table 6. The number of missed or overlooked diagnosis of VTE.  
9. Miscellaneous 
The remaining 45 cases were a broad selection of the many different causes there may be for 
acquiring VTE, as well as a few that had a prophylaxis or a treatment of VTE that wasn’t up 
to the standard of the experienced specialist (Table 7).  
 
Rare or miscellaneous N N approved 
Upper extremity 20 10 
Sinus thrombosis 11 9 
Venous puncture or catheterization 4 4 
Wrong prophylaxis or treatment 4 4 
VTE i spite of correct treatment 3 0 
Mesenteric venous thrombosis 2 1 
Paradox embolism 1 1 
 45 29 
Table 7.  Rare or miscelleanous patients. 
The cases of cerebral sinus thrombosis were all caused by birth control medication. Three of 
the cases of venous puncture were caused by blood donation; such claims are nearly always 
approved by the DPIA. Two of the 45 patients died. 
There were 83 claims that went on to the appeal board, and of these 15 had the decision of 
the DPIA altered. The changes of decisions nearly all concerned the size of the 
compensation. One claim went on to the high court. It concerned a male of 33 years, who 
had a percutaneous endoscopic ligature of the spermatic veins for a hydrocele testis. 
Afterwards he suffered a hemorrhage in the scrotal sac and a venous thrombosis in the leg. 
The compensation in the DPIA was € 95.165, and this decision was upheld both before the 
appeal board and in the high court. 
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10. Discussion 
The standard prophylaxis in Denmark is usually given only for the duration of admittance 
to hospital, or until the patient is well mobilized. During recent times, a number of studies 
have suggested that this is not enough, and that prophylaxis should be given for 6 or 8 
weeks after surgery (3, 4). The price would be manageable, and the logistics could probably 
be overcome. Why do we accept that hundreds and hundreds of patients go without 
prophylaxis for the period they are at risk?  
Also, it is not rare to see a patient described as “well mobilized” and therefore have his 
prophylaxis discontinued, when in fact he is only out of bed for a few hours a day and then 
only sitting in a chair. The sitting position, if anything, increases the stasis of blood in the 
veins of the legs, and therefore probably also increases the risk of VTE. The development of 
tablets for VTE prophylaxis may change this state of affairs in the future, since it will make 
the administration of medication simpler (5, 6).  
The treatment of VTE goes hand in hand with the prevention of the disease. When you have 
seen the damage that VTE can do to patients, you are likely to go far to prevent a single case. 
There exists well-proven mechanical as well as biochemical methods with very few side 
effects.  All of these 688 cases must be viewed as potentially preventable with the exception 
of the 3 cases, where VTA occurred in spite of the fact that correct prophylaxis was given. 
Off course it is not possible to prevent all cases, which you can se by the fact that these 3 
cases occurred. But this must not be given as an excuse to omit prophylaxis. 
It is inexcusable to perform major invasive treatment without prophylaxis, and probably the 
medical profession should consider extending the indications as well as the duration of 
prophylaxis. The cost of doing this will be balanced against the gain from not having to treat 
the VTE-cases and the tax returns from the survivors of complications to VTE (7).  
It should probably also be considered to screen the women for coagulation deficits before 
they are placed on contraceptive medication. Certainly, it is clear from our records, that the 
medical profession should consider the differential diagnosis of VTE in patients on 
contraceptive drugs more often. 
For the DPIA it is also a question whether you should approve claims from women, who 
have a coagulation defect like Leiden factor-5 mutation? There were only 17 cases where our 
patients had been tested positive for this genetic defect. The true number is probably much 
higher. Normally, the DPIA does not approve claims, when a patient has a disposition to the 
injury. It can be argued, however, that the experienced specialist would not prescribe 
contraceptive drugs to a patient with Leiden-5 mutation. It is therefore the normal practice 
of the DPIA to approve these claims.  
The fractures that are treated by non-invasive means are by no means immune from VTE. A 
recent metaanalysis of the question of prophylaxis to these patients (8) states that 
ambulatory patients with temporary lower leg immobilization who are over 50, in a rigid 
cast, non-weight bearing or with a severe injury should be considered as a risk group for 
VTE.  The present opinion is however, that the VTE in these cases is caused by the trauma 
and not the treatment. The patient that dies from PE probably doesn’t care.  We think that it 
should be seriously considered to include these patients in an anti-VTE program. 
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We realize that there are many claims that never comes to the knowledge of the DPIA. The 
reasons for this are many: Ignorance of the law, resignation in the face of a serious disease 
complicated by the injury, the bother of the application procedure, fear of alienating the 
physician etc. We have tried several methods in order to achieve a more precise estimate of 
this problem (9, 10). Our best estimate is now that there are at least 4 – 5 patient injuries for 
each claim. 
The risk of VTE increases with malignancy, infections, reoperations and surgery close to the 
large veins. The prophylaxis should be adjusted accordingly. It is about time that the 
medical profession starts to realize that posttraumatic or postoperative VTE is not an 
inevitable event. It may be prevented by a number of quite effective measures, but a change 
in attitude from the medical profession is required.  
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